Cargando…

A Novel ZIP4-HDAC4-VEGFA Axis in High-Grade Serous Ovarian Cancer

SIMPLE SUMMARY: Despite tremendous research efforts, epithelial ovarian cancer (EOC) remains one of the most difficult cancers to detect early and treat successfully for >5-year survival. We have recently shown that ZIP4, a zinc transporter, is a novel cancer stem cell (CSC) marker and a therapeu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fan, Qipeng, Li, Lihong, Wang, Tian-Li, Emerson, Robert E., Xu, Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345154/ https://www.ncbi.nlm.nih.gov/pubmed/34359722 http://dx.doi.org/10.3390/cancers13153821

Ejemplares similares

ZIP4 Is a Novel Cancer Stem Cell Marker in High-Grade Serous Ovarian Cancer
por: Fan, Qipeng, et al.
Publicado: (2020)

The novel ZIP4 regulation and its role in ovarian cancer
por: Fan, Qipeng, et al.
Publicado: (2017)

HDAC6 Degradation Inhibits the Growth of High-Grade Serous Ovarian Cancer Cells
por: Ali, Ahlam, et al.
Publicado: (2020)

Clinical Relevance of Increased Endothelial and Mesothelial Expression of Proangiogenic Proteases and VEGFA in the Omentum of Patients with Metastatic Ovarian High-Grade Serous Carcinoma()()
por: Winiarski, Boleslaw K., et al.
Publicado: (2014)

ZNF385B and VEGFA Are Strongly Differentially Expressed in Serous Ovarian Carcinomas and Correlate with Survival
por: Elgaaen, Bente Vilming, et al.
Publicado: (2012)

FOXM1 is a downstream target of LPA and YAP oncogenic signaling pathways in high grade serous ovarian cancer
por: Fan, Qipeng, et al.
Publicado: (2015)

Class I-Histone Deacetylase (HDAC) Inhibition is Superior to pan-HDAC Inhibition in Modulating Cisplatin Potency in High Grade Serous Ovarian Cancer Cell Lines
por: Bandolik, Jan J., et al.
Publicado: (2019)

Low-grade Serous Ovarian Carcinoma
por: Ricciardi, Enzo, et al.
Publicado: (2018)

The disruption of the CCDC6 – PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
por: Morra, Francesco, et al.
Publicado: (2022)

High grade serous ovarian carcinomas originate in the fallopian tube
por: Labidi-Galy, S. Intidhar, et al.
Publicado: (2017)

Identification of Novel Fusion Transcripts in High Grade Serous Ovarian Cancer
por: Newtson, Andreea, et al.
Publicado: (2021)

Testing for NRAS Mutations in Serous Borderline Ovarian Tumors and Low-Grade Serous Ovarian Carcinomas
por: Sadlecki, Pawel, et al.
Publicado: (2018)

Development of Low-Grade Serous Ovarian Carcinoma from Benign Ovarian Serous Cystadenoma Cells
por: Dey, Puja, et al.
Publicado: (2022)

Cell Origins of High-Grade Serous Ovarian Cancer
por: Kim, Jaeyeon, et al.
Publicado: (2018)

CDK4/6 inhibition as maintenance and combination therapy for high grade serous ovarian cancer
por: Iyengar, Mangala, et al.
Publicado: (2018)

The role of distinct BRD4 isoforms and their contribution to high-grade serous ovarian carcinoma pathogenesis
por: Drumond-Bock, Ana Luiza, et al.
Publicado: (2021)

High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer
por: Qin, Lianzhi, et al.
Publicado: (2017)

Inhibition of VEGFA Increases the Sensitivity of Ovarian Cancer Cells to Chemotherapy by Suppressing VEGFA-Mediated Autophagy
por: Li, Xia, et al.
Publicado: (2020)

4D Doppler Ultrasound in High Grade Serous Ovarian Cancer Vascularity Evaluation—Preliminary Study
por: Kudla, Marek Jerzy, et al.
Publicado: (2021)

Targeting the Microenvironment in High Grade Serous Ovarian Cancer
por: Nwani, Nkechiyere G., et al.
Publicado: (2018)

The Tumor Microenvironment of High Grade Serous Ovarian Cancer
por: Stack, M. Sharon, et al.
Publicado: (2018)

Proteome profiling of low grade serous ovarian cancer
por: zadeh fakhar, Haniyeh Bashi, et al.
Publicado: (2019)

High-grade serous ovarian cancer: the clone wars
por: Salomon-Perzyński, Aleksander, et al.
Publicado: (2017)

Molecular Management of High-Grade Serous Ovarian Carcinoma
por: Punzón-Jiménez, Paula, et al.
Publicado: (2022)

In vivo modeling of metastatic human high-grade serous ovarian cancer in mice
por: Kim, Olga, et al.
Publicado: (2020)

Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma
por: Jiang, Rosie T., et al.
Publicado: (2017)

Expression of hypothalamic-pituitary-gonadal axis-related hormone receptors in low-grade serous ovarian cancer (LGSC)
por: Feng, Zheng, et al.
Publicado: (2017)

A novel epigenetic CREB-miR-373 axis mediates ZIP4-induced pancreatic cancer growth
por: Zhang, Yuqing, et al.
Publicado: (2013)

miR-6086 inhibits ovarian cancer angiogenesis by downregulating the OC2/VEGFA/EGFL6 axis
por: Wu, Binhua, et al.
Publicado: (2020)

Identification of AK4 as a novel therapeutic target for serous ovarian cancer
por: Huang, Minmin, et al.
Publicado: (2020)

Cardiophrenic lymph node metastasis in low-grade serous ovarian adenocarcinoma
por: Serna-Gallegos, Tasha, et al.
Publicado: (2016)

SLCO4A1 expression is associated with activated inflammatory pathways in high-grade serous ovarian cancer
por: Koller, Stephanie, et al.
Publicado: (2022)

HDAC9 Contributes to Serous Ovarian Cancer Progression through Regulating Epithelial–Mesenchymal Transition
por: Xu, Long, et al.
Publicado: (2022)

Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma
por: Ducie, Jennifer, et al.
Publicado: (2017)

First-Line Management of Advanced High-Grade Serous Ovarian Cancer
por: Mahmood, Reem D., et al.
Publicado: (2020)

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer
por: Morgan, Robert D., et al.
Publicado: (2018)

Low-grade serous carcinoma with extensive osseous metaplasia arising from ovarian serous cystadenofibroma
por: Ribeiro e Ribeiro, Renan, et al.
Publicado: (2021)

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
por: Hunter, Sally M., et al.
Publicado: (2015)

Novel antimyeloma therapeutic option with inhibition of the HDAC1-IRF4 axis and PIM kinase
por: Harada, Takeshi, et al.
Publicado: (2022)

The peritoneal tumour microenvironment of high-grade serous ovarian cancer
por: Leinster, D Andrew, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1169iivhcem7205jsubvhvkum7